CL2018000164A1 - Vector recombinante del virus orf. - Google Patents

Vector recombinante del virus orf.

Info

Publication number
CL2018000164A1
CL2018000164A1 CL2018000164A CL2018000164A CL2018000164A1 CL 2018000164 A1 CL2018000164 A1 CL 2018000164A1 CL 2018000164 A CL2018000164 A CL 2018000164A CL 2018000164 A CL2018000164 A CL 2018000164A CL 2018000164 A1 CL2018000164 A1 CL 2018000164A1
Authority
CL
Chile
Prior art keywords
orf
virus
vector
recombinant vector
recombining
Prior art date
Application number
CL2018000164A
Other languages
English (en)
Inventor
Rziha Hans-Joachim
Amann Ralf
Original Assignee
Univ Tuebingen Medizinische Fakultaet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tuebingen Medizinische Fakultaet filed Critical Univ Tuebingen Medizinische Fakultaet
Publication of CL2018000164A1 publication Critical patent/CL2018000164A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8572—Animal models for proliferative diseases, e.g. comprising an oncogene
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8581—Animal models for infectious diseases, e.g. AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN VECTOR RECOMBINANTE DEL VIRUS ORF, UNA CÉLULA QUE CONTIENE TODO EL VECTOR RECOMBINANTE DEL VIRUS ORF, UNA COMPOSICIÓN QUE CONTIENE AL VECTOR RECOMBINANTE DEL VIRUS ORF DE ACUERDO CON LA INVENCIÓN Y/O QUE CONTIENE LA CÉLULA DE ACUERDO CON LA INVENCIÓN, EL USO DEL VECTOR RECOMBINANTE DEL VIRUS ORF DE ACUERDO CON LA INVENCIÓN PARA LA PRODUCCIÓN DE UN GEN EXTRAÑO. LA INVENCIÓN SE REFIERE TAMBIÉN A UNA MOLÉCULA DE ÁCIDO NUCLEICO PARA UN PROMOTOR DEL VECTOR DEL VIRUS ORF.
CL2018000164A 2015-07-20 2018-01-19 Vector recombinante del virus orf. CL2018000164A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102015111756.8A DE102015111756A1 (de) 2015-07-20 2015-07-20 Rekombinanter Orf-Virus-Vektor

Publications (1)

Publication Number Publication Date
CL2018000164A1 true CL2018000164A1 (es) 2018-08-24

Family

ID=56507584

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000164A CL2018000164A1 (es) 2015-07-20 2018-01-19 Vector recombinante del virus orf.

Country Status (17)

Country Link
US (2) US11286500B2 (es)
EP (1) EP3325631A1 (es)
JP (2) JP7092663B2 (es)
KR (2) KR102433709B1 (es)
CN (2) CN116445547A (es)
AU (2) AU2016294855B2 (es)
BR (1) BR112018001121A2 (es)
CA (1) CA2993263A1 (es)
CL (1) CL2018000164A1 (es)
DE (1) DE102015111756A1 (es)
EA (1) EA201890351A1 (es)
IL (1) IL257025B2 (es)
MX (1) MX2018000845A (es)
NZ (1) NZ739286A (es)
PH (1) PH12018500155A1 (es)
WO (1) WO2017013023A1 (es)
ZA (1) ZA201801091B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
CN112512560A (zh) * 2018-03-07 2021-03-16 特兰斯吉恩股份有限公司 副痘病毒属载体
CN112522215B (zh) * 2019-09-18 2023-06-02 重庆市畜牧科学院 一种缺失008基因的重组羊口疮病毒及其构建方法
EP3871690A1 (en) 2020-02-27 2021-09-01 Technische Hochschule Mittelhessen Method for virus production
CA3192853A1 (en) 2020-08-13 2022-02-17 Suzhou Prajna Biotech Co., Ltd. Mutant orf viruses and uses thereof
EP3957322A1 (en) 2020-08-19 2022-02-23 Eberhard Karls Universität Tübingen Medizinische Fakultät Recombinant poxviridae vector expressing co-stimulatory molecules

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2243937T3 (es) * 1994-04-29 2005-12-01 Baxter Healthcare S.A. Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños.
US6365393B1 (en) * 1996-02-28 2002-04-02 Bayer Aktiengesellschaft Parapoxviruses containing foreign DNA, their production and their use in vaccines
DE19639601A1 (de) * 1996-02-28 1997-09-04 Bayer Ag Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen
KR20000005120A (ko) * 1996-03-29 2000-01-25 스칸드레트 존 디 파라폭스바이러스 벡터
US20110014706A2 (en) * 1998-12-14 2011-01-20 Monsanto Technology Llc Arabidopsis thaliana Genome Sequence and Uses Thereof
US7868149B2 (en) * 1999-07-20 2011-01-11 Monsanto Technology Llc Plant genome sequence and uses thereof
US20130326723A1 (en) * 1999-05-06 2013-12-05 Thomas J. La Rosa Soy nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
MXPA02011545A (es) * 2000-05-24 2003-06-06 Merial Sas Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
CN1331196A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——妊娠特异性β1－糖蛋白9.02和编码这种多肽的多核苷酸
DE10122233A1 (de) * 2000-07-11 2002-01-24 Bayer Ag Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
US6372455B1 (en) * 2001-04-19 2002-04-16 Arizona Board Of Regents Recombinant vaccinia viral vectors
NZ512341A (en) * 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
DE10221411B4 (de) * 2002-05-14 2004-07-08 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Rekombinantes Fowlpox-Virus
US7943373B2 (en) * 2004-09-29 2011-05-17 Oncolys Biopharma, Inc. Telomelysin/GFP-expressing recombinant virus
EP1764107A1 (en) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
KR100794218B1 (ko) * 2005-11-28 2008-01-11 재단법인서울대학교산학협력재단 ＤＮｐ63의 프로모터를 이용한 항암제 스크리닝 방법
KR100985702B1 (ko) * 2008-07-01 2010-10-06 주식회사 쎌바이오텍 페디오코커스 펜토사세우스에서 분리된 신규한 플라스미드및 그의 용도
WO2011101696A1 (en) * 2010-02-18 2011-08-25 Cellectis Improved meganuclease recombination system
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
KR20150015551A (ko) * 2010-05-21 2015-02-10 조에티스 엘엘씨 광견병 바이러스 항원을 함유하는 파라폭스바이러스 벡터
MX2013000787A (es) * 2010-07-20 2013-08-08 Zoetis Llc Vectores de parapoxvirus.
WO2013172721A1 (en) * 2012-05-18 2013-11-21 Wise Lyn Marie Combination treatments and compositions for wound healing
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor

Also Published As

Publication number Publication date
CA2993263A1 (en) 2017-01-26
IL257025A (en) 2018-03-29
AU2020264302B2 (en) 2023-06-08
AU2020264302A1 (en) 2020-11-26
JP2020188776A (ja) 2020-11-26
JP2018523491A (ja) 2018-08-23
MX2018000845A (es) 2018-08-16
AU2016294855B2 (en) 2020-08-06
IL257025B1 (en) 2024-02-01
CN108026542B (zh) 2022-12-09
KR102259277B1 (ko) 2021-06-01
EA201890351A1 (ru) 2018-06-29
DE102015111756A1 (de) 2017-01-26
EP3325631A1 (de) 2018-05-30
US11286500B2 (en) 2022-03-29
KR102433709B1 (ko) 2022-08-18
ZA201801091B (en) 2022-07-27
IL257025B2 (en) 2024-06-01
BR112018001121A2 (pt) 2018-09-11
US20180148739A1 (en) 2018-05-31
AU2016294855A1 (en) 2018-02-15
NZ739286A (en) 2019-10-25
CN108026542A (zh) 2018-05-11
CN116445547A (zh) 2023-07-18
KR20210064427A (ko) 2021-06-02
KR20180058705A (ko) 2018-06-01
US20220204992A1 (en) 2022-06-30
JP7092663B2 (ja) 2022-06-28
PH12018500155A1 (en) 2018-07-23
WO2017013023A1 (de) 2017-01-26

Similar Documents

Publication Publication Date Title
CL2018000164A1 (es) Vector recombinante del virus orf.
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
CY1123853T1 (el) Ρυθμιστες nrf2
BR112018007017A2 (pt) polipeptídeos
CL2018000587A1 (es) Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017)
CL2018000124A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
BR112018011881A2 (pt) proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
ES2743232T3 (es) Métodos para la activación o eliminación controlada de células terapéuticas
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
EP3741849A3 (en) Protease variants and polynucleotides encoding same
MX2018001531A (es) Medio de cultivo celular complementado con taurina y metodos de uso.
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
CL2018000158A1 (es) Composiciones y métodos para inhibir la expresión del gen alas1 (divisional de solicitud 20160772)
MX2022013454A (es) Moduladores de la actividad del complemento.
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
EA201691754A1 (ru) Рекомбинантный микроорганизм, экспрессирующий аналог авермектина, и его применение
MX2018001055A (es) Promotores para mejorar la expresion en poxvirus.
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
BR112018001255A2 (pt) composto direcionado à il-23a e fator de ativação de células b (baff) e seus usos
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2016003095A1 (es) Péptidos como agonistas de la oxitocina
WO2012162342A3 (en) Influenza vaccines containing modified adenovirus vectors